P/E ratio for Portage Biotech (PRTG)
P/E ratio as of June 2024 (TTM): -0.0385
According to Portage Biotech's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0385307. At the end of 2022 the company had a P/E ratio of -4.48.
P/E ratio history for Portage Biotech from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.48 | -28.57% |
| 2021 | -6.27 | -84.3% |
| 2020 | -40.0 | 132.73% |
| 2019 | -17.2 | -8391.67% |
| 2018 | 0.2072 | -101.55% |
| 2017 | -13.3 | -1125.29% |
| 2016 | 1.30 | -127.53% |
| 2015 | -4.72 | -24.94% |
| 2014 | -6.29 | 6.57% |
| 2013 | -5.90 | 100.81% |
| 2012 | -2.94 | 174.29% |
| 2011 | -1.07 | -49.81% |
| 2010 | -2.14 | -69.83% |
| 2009 | -7.08 | -52.04% |
| 2008 | -14.8 | -74.31% |
| 2007 | -57.5 | 110.27% |
| 2006 | -27.3 | 6362.66% |
| 2005 | -0.4228 | -103.34% |
| 2004 | 12.7 | 28.78% |
| 2003 | 9.82 | -890.05% |
| 2002 | -1.24 | -331.72% |
| 2001 | 0.5367 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | 8,551.10% | Bahamas |
 NRC Health
NRC | 23.8 | -61,799.11% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.